Pamidronate (disodium pentahydrate)

Pamidronate disodium pentahydrate, the second-generation nitrogen-containing bisphosphonate, is an inhibitor of bone loss. Pamidronate disodium pentahydrate significantly inhibits subchondral bone loss in early osteoarthritis by upregulating the expression of osteoprotegerin in cartilage and subchondral bone, and inhibiting the expression of RANKL and MMP-9 in both tissues, as well as TLR-4 in cartilage, thereby alleviating cartilage degeneration. Additionally, Pamidronate disodium pentahydrate can inhibit the signaling of Wnt and β-catenin, and is applicable for research on osteoporosis and osteosarcoma[1][2][3][4].

Product Specifications

CAS Number

[109552-15-0]

UNSPSC

12352211

Hazard Statement

H302, H319

Target

RANKL/RANK ; Toll-like Receptor (TLR) ; Wnt; β-catenin

Type

Reference compound

Related Pathways

Immunology/Inflammation; NF-κB; Stem Cell/Wnt

Field of Research

Cancer; Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Pamidronate-disodium-pentahydrate.html

Purity

98.0

Solubility

DMSO : < 1 mg/mL|H2O : 7 mg/mL (ultrasonic)

Smiles

OC(P(O)(O[Na])=O)(CCN)P(O)(O[Na])=O.O.O.O.O.O

Molecular Formula

C3H19NNa2O12P2

Molecular Weight

369.11

Precautions

H302, H319

References & Citations

[1]Kubalek I, et al. Treatment of reflex sympathetic dystrophy with pamidronate: 29 cases. Rheumatology (Oxford). 2001 Dec;40(12):1394-7.|[2]Zarychanski R, et al. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol. 2006 Jan;81(1):73-5.